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Abstract
To date, CCR5 variants remain the only human genetic factors to be confirmed to impact HIV-1
acquisition. However, protective CCR5 variants are largely absent in African populations, in
which sporadic resistance to HIV-1 infection is still unexplained. Here we perform a genome-wide
association study (GWAS) in a population of 1,532 individuals from Malawi, a country with high
prevalence of HIV-1 infection, to investigate whether common genetic variants associate with
HIV-1 susceptibility in Africans. Using single nucleotide polymorphisms (SNPs) present on the
genome-wide chip, we also investigated previously reported associations with HIV-1
susceptibility or acquisition. Recruitment was coordinated by the Center for HIV/AIDS Vaccine
Immunology at two sexually transmitted infection clinics. HIV status was determined by HIV
rapid tests and nucleic acid testing.
After quality control, the population consisted of 848 high-risk seronegative and 531 HIV-1
seropositive individuals. Logistic regression testing in an additive genetic model was performed
for SNPs that passed quality control. No single SNP yielded a significant P-value after correction
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for multiple testing. The study was sufficiently powered to detect markers with genotype relative
risk ≥ 2.0 and minor allele frequencies ≥12%. This is the first GWAS of host determinants of
HIV-1 susceptibility, performed in an African population. The absence of any significant
association can have many possible explanations: rarer genetic variants or common variants with
weaker effect could be responsible for the resistance phenotype; alternatively, resistance to HIV-1
infection might be due to non-genetic parameters or to complex interactions between genes,
immunity and environment.
Keywords
Human immunodeficiency virus (HIV-1); acquisition; resistance; Genome Wide Association
Study (GWAS); Africa
INTRODUCTION
Throughout the history of the AIDS epidemic, subsets of individuals have appeared to
resistHIV-1 infection despite multiple exposures to the virus [1, 2]. However, almost 30
years after the first description of AIDS, variants in the CCR5 gene remain the only human
genetic variants that have been proven to significantly impact HIV-1 acquisition [3, 4].
When present in homozygous or combined heterozygous form, the Δ32 deletion and the
much rarer m303T>A point mutation confer complete resistance to infection by viruses that
use CCR5 as co-receptor. Nevertheless, these mutations only explain a fraction of the
apparently HIV-1 exposed, yet uninfected cases. Importantly, they are only found in
individuals with a northern European or central Asian heritage and thus are not responsible
for resistance observed in African populations [5]. The identification of additional human
genetic factors influencing HIV-1 susceptibility would shed new light on transmission
mechanisms and pathogenesis, and potentially suggest novel preventive or therapeutic
approaches.
Genome-wide association studies (GWAS) are a widely accepted approach for the
investigation of common genetic variation in the human genome [6]. Not relying on
candidate gene selection, these hypothesis-free studies have the potential to implicate new
genomic regions and pathways affecting complex human traits and diseases. Several recent
GWAS have provided a detailed description of how common variation influences control of
HIV-1 in infected individuals from European and African America ancestry [7 – 10]. To
date, however, there have been no reported GWAS studies of HIV-1 resistance/
susceptibility. A major reason for this has been the difficulty in recruiting enough well-
characterized, highly exposed, yet seronegative individuals for an adequately powered study
[11]. We here describe the first GWAS of host determinants of HIV-1 susceptibility,
performed in a homogeneous African population.
METHODS
STUDY POPULATION
To identify common gene variants influencing HIV-1 acquisition in the highly affected Sub-
Saharan African region, we performed a genome-wide association study in a population of
over 1,500 individuals recruited from two Sexually Transmitted Infections (STI) clinics in
Blantyre and Lilongwe, Malawi. These clinics are integrated in the Center for HIV/AIDS
Vaccine Immunology (CHAVI) Clinical Core. The prevalence of HIV-1 infection in Malawi
is one of the highest in the world, with an estimated 12% of adults infected [12]. An even
higher prevalence (around 30%) was observed among the patients screened for this study.
We therefore assume that sexually active individuals recruited at these sites were likely to
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have been exposed to the HIV virus. We did not, however, collect information about
individual exposure level, sexual orientation, or intravenous drug use.
This study was approved by all local and by the sponsoring institution’s ethics committees.
All participants consented to a blood sample collection and genetic testing. HIV status was
determined by HIV rapid tests and nucleic acid testing (NAT): a positive HIV-1 diagnosis
required a confirmed positive rapid test, and a negative HIV-1 diagnosis was based on two
negative rapid tests followed by a negative NAT, or discordant results from rapid tests with
a negative NAT.
GWAS GENOTYPING AND QUALITY CONTROL
DNA samples were genotyped using either the Illumina Human1M or 1M-Duo DNA
Analysis BeadChips. Genotype clustering was performed using the Infinium BeadStudio
program. Samples that obtained a very low intensity or call rate (<99%) were excluded.
Further quality control was performed using PLINK [13], by checking the genetic gender
and removing the gender misclassified individuals. Then, cryptic relatedness was assessed
using pair-wise identity-by-descent (IBD). All pairs of DNA samples showing ≥0.125
(estimated proportion of alleles IBD) were individually inspected, and one sample in each
pair was excluded from further analyses.
To account for the possibility of spurious associations resulting from residual population
stratification, we used a modified EIGENSTRAT method to correct for population ancestry
within the remaining case and control data [14].
GENOME-WIDE ASSOCIATION ANALYSIS
We searched for an association between HIV infection status and each of the single-marker
genotypes by logistic regression in an additive genetic model using PLINK, correcting for
age, gender and the significant principal component analysis axes identified with
EIGENSTRAT. Bonferroni correction was applied to correct for multiple testing; however,
we first used a linkage disequilibrium pruning procedure to remove entirely dependent
markers, defined as r2=1, and then used the Bonferroni adjustment based on this reduced set
of SNPs. This allowed for improved control of multiple marker testing.
Power calculations for association analysis were performed using the genetic power
calculator (GPC) (available at http://pngu.mgh.harvard.edu/~purcell/gpc/)[15].
Previous studies have reported variants that might influence HIV-1 susceptibility in other
populations. We investigated whether these previously reported associations could be
replicated in a genome-wide context within the Malawi study by looking at the SNP variants
that have previously been published with a p<0.05. If the originally reported SNP was not
genotyped, we report the best available proxy SNP based on the HapMap YRI data, also
reporting the r2 value. Moreover, we report the SNP with the lowest p value for each of the
previously reported candidate genes.
RESULTS
A total of 1,532 Chichewa-speaking individuals recruited from Malawi STI clinics between
December 2006 and August 2008 were genotyped. Of these, n=922 (60.2%) were HIV
negative cases and n=610 (39.8%) were HIV positive controls.
DNA samples from 86 individuals (6%) did not pass initial quality control filtering. An
additional 19 individuals were removed due to gender misclassification, and 37 individuals
were removed due to cryptic relatedness. In addition, to assess population stratification,
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PCA was performed on a subset of 191,212 SNPs not in Linkage Disequilibrium. In the first
iteration, 11 outliers were identified and excluded. Following the above quality control
steps, the population adopted in the association testing consisted of 848 HIV-negative cases,
of which 52% were females, and531 HIV-positive controls, of which 62% were females.
Age distribution significantly differed between the HIV-1 seropositive and seronegative
samples (median 29 [range, 18–62] vs. 29 [range, 20–66], p=0.002).
Logistic regression testing in an additive genetic model was performed for the 844,489single
markers that passed quality control. No single SNP yielded a P-value below the Pcutoff =
6.03×10−8 (Supplementary Figure 1, Manhattan Plot). An annotated list of all markers
obtaining a P-value less than 2×10−4 was generated using WGA viewer software[16]
(Supplementary Table1).
The Q-Q plot of the GWAS P-value distribution shows that the distributions of the observed
and expected P-values are very similar with a lambda value of 0.9982 that suggests no
inflation of association signals after correction for population stratification.
As an additional subset analysis, based on previously published reports of variants
associated with HIV-1 susceptibility, we checked the p values across 22candidate genes of
36previously reported candidate SNPs or their closest proxies within 100kb. For each gene,
we report the candidate SNPs when possible, and otherwise the best available proxy. We
also report the lowest p-value identified within each candidate gene, first uncorrected and
then corrected for the number of SNPs analysed in that gene (Table 1). However, failure to
find a significant association within a candidate gene where the originally reported SNP was
not examined does not translate to a failure to replicate the original association. We were
able to directly test 17 of the 36 SNPs previously reported. For those SNPs not present on
the chips, none have good proxies r2>0.8. Of these17SNPs, only rs1946518–IL18, originally
reported to increase susceptibility to HIV-1 infection in a pediatric Brazilian population
(p=0.02) [17], was significant in our Malawi study at the p<0.05 level where the C allele is
significantly more represented in the HIV positive Malawi group than the high-risk
seronegative group (67 vs. 62%, p=0.004). The meta p-value remains non-significant at the
genome-wide level, p=0.001, Stouffer’s z trend.
Of the 22 candidate genes tested, 13 genes were found to have at least one SNP significant
at the p<0.05 level, with the most strongly associated gene, CXCL12 [18], represented by 8
SNPs below the p<0.001 level. After correcting for the number of SNPs per gene, only
rs2437935–CXCL12 remained significant with a p-value of 0.01 (corrected for 179 SNPs).
However, that p-value increased to 0.085 when correcting for all 1,208 SNPs tested across
the 22candidate genes.
DISCUSSION
Here we performed a GWAS of determinants of resistance to HIV-1 infection by testing for
associations at over 800,000 SNPs. We failed to detect significant signals for differences in
HIV-1 susceptibility in this study of samples collected from Malawi STI clinics. Our lowest
p-value was 3.97×10−6, which is substantially higher than the Pcutoff estimated to be
6.03×10−8 on this dataset.
This is, to our knowledge, the first report of a genome-wide search for genetic variants
associated with differences in susceptibility to HIV-1 infection. We studied a homogenous
Sub-Saharan African population, comparing genotypes of HIV-infected and non-infected
subjects that attended the same STI clinics in Malawi. Due to the high prevalence of HIV-1
in this region, it is believed that HIV negative individuals attending these STI clinics are in a
high-risk category and are likely to have been exposed to the virus. However, clinical data
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on exposure details was not collected, and as such, we had no information on the number
and type of sexual contacts, the number of partners, sexual orientation, co-infections, or
discordance in long-term relationship with a known HIV-1 infected partner.
Failing to detect a GWAS signal in this study can have many possible explanations,
including the hypothesis that resistance or reduced susceptibility to HIV-1 infection might
be due to complex interactions between innate and acquired immunity, modulated by
epistasis and environment. Non-genetic factors might include mode of transmission;
concurrent STI infections; viral load of infected partner; and multiple viral strain exposures.
However, it is still possible that resistance or reduced susceptibility to HIV-1 infection is
due to common human genetic variants not identified in the present study, either because
they are not represented, directly or indirectly, on the genome-wide genotyping chip that we
used (the Illumina 1M-Duo chip is the best currently available platform for investigating
African population [19], but it still has suboptimal coverage), or because they have relatively
weak effects, undetected with our sample size. Even when there is incomplete exposure in
the high-risk seronegative group, there is still an expectation of allele frequency imbalance
since the HIV-positive individuals are infectable, and the power depends on the precise
degree of exposure. Under the assumption that all seronegative individuals recruited at the
Malawi STI clinics have some protection, given MAFs of 5% and 20%, under a additive
disease model with a type I error rate of 6.03×10−8, our Malawi study provides at least 80%
power to detect an association for HIV-1 reduced susceptibility, with genotype relative risks
(GRR) of ≥2.65 and >1.7, respectively. Moreover, the power to detect markers with GRRs
≥2.0 was 13%, 68%, and 99% for markers with 5%, 10%, and 20% MAFs, respectively.
Considering a larger population and thus increasing power might detect a signal from
African populations. An alternative hypothesis to common causation would be that rare
variants are causal, and therefore, resequencing efforts on highly exposed, HIV-1 uninfected
individuals might return informative data on the genetic determinants of HIV-1 resistance.
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Refer to Web version on PubMed Central for supplementary material.
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